• Xingneng Xuanguang

  Participated · Series A · Jun 2026

  Xingneng Xuanguang is a fusion technology company formed with support from the University of Science and Technology of China (USTC) that develops high‑performance field‑reversed configuration (FRC) fusion prototypes. The team is led by founder Professor Sun Xuan, who has nearly 30 years of experience and led KMAX, China’s first FRC device, and the core staff includes USTC professors and PhD students who make up over 40% of the team. The company pursues a pulsed magnetic compression FRC approach emphasizing compact design, high specific pressure and relatively low system cost. It reported recent milestones including Xeonova‑1 achieving a plasma discharge in February 2025 and the FLAME anti‑magnetic‑mirror device reaching first plasma discharge in January 2026, marking its transition to physical experiments. Xingneng Xuanguang plans systematic upgrades to heating, diagnostics and plasma control to improve plasma temperature, density and confinement time. The company projects achieving megawatt‑scale fusion power and Q>1 by 2030 and constructing a 100 MW engineering reactor with grid connection by 2035.

• Thousand Oaks Biopharmaceuticals

  Participated · Series C · Mar 2021

  Thousand Oaks Biopharmaceuticals (澳斯康) is a CDMO and cell‑culture media biotech focused on integrated CMC biomanufacturing services spanning R&D, process development, production, logistics, technical support and after‑sales. Its affiliate Jianshun Bio (健顺生物) develops and manufactures serum‑free, chemically defined mammalian cell culture media and is described as a leading domestic supplier, serving 100+ clinical projects including over 20 phase‑III trials. On the CDMO side the company has served more than 40 clients since launching that business and reports rapidly growing annual orders. Operational assets include a 10,000 m2 cGMP facility with 2,000L batch and 500L perfusion production capacity and formulation lines for vial filling/lyophilization and pre‑filled syringes/cartridges; the company says it has passed audits to NMPA, FDA and EMA standards. The company states the new funding will be used to expand CDMO and media production capacity and to build a global‑scale media production base and an internationally leading CDMO platform. Thousand Oaks emphasizes an international management and technical team and positions its proprietary serum‑free media as enabling domestic substitution of previously imported products. Thousand Oaks Biopharmaceuticals is a biopharma firm. The company completed a Series B financing, raising 450 million yuan (about $64 million). The round was led jointly by CICC Capital’s sub‑fund CICC Jiatai and CITIC Securities’ private equity arm Goldstone Investment Limited. The article does not disclose the company’s product pipeline or future plans. No operating metrics (revenue, users) or use of proceeds are provided in the report. The financing strengthens the company’s capital base at the Series B stage. TOBIO is an integrated global CMC organization supplying GMP cell culture media and biomanufacturing capabilities. It offers integrated CMC services including cell line development from DNA sequences, process and bioanalytical development, customized cell culture media development, clinical material supply, commercial manufacturing, bioanalytical services and regulatory filings. The company closed a $45 million Series A to advance its phase II CDMO business and to fund construction of large-scale cell culture media (LSCCM) cGMP manufacturing facilities in Haimen, Nantong, China. TOBIO says the new plant will be the world’s largest cell culture medium manufacturing facility and will increase current media production capacity. Management frames the expansion as enabling strategic partnerships to accelerate biologics development from bench to market and to help partners provide affordable and accessible biologics. The company has global footprints in Shanghai, Haimen and Lanzhou in China, and Thousand Oaks and Pleasanton, California.

No current team members are available.